In ICSI patients with high risk of ovarian hyperstimulation syndrome (OHSS), are antagonist cycles triggered by gonadotropin releasing hormone (GNRH) agonist with a specialized luteal support regimen associated with comparable ongoing pregnancy rate (OPR) and less OHSS than those triggered by hCG?
Introduction
In ART, we aim to achieve high pregnancy rates with the safest and most convenient protocols of controlled ovarian stimulation (COS) and luteal phase support. An essential step in the IVF/ICSI protocols is final oocyte maturation. For this purpose, exogenous hCG was used for years as a substitute of the endogenous LH surge. Although both can bind to and stimulate the same receptors (Kessler et al., 1979) , the longer half life of hCG produces a prolonged luteotrophic effect, multiple corpora lutea and supraphysiologic steroids levels securing good reproductive outcomes (Itskovitz et al., 1991) . This prolonged luteotrophic effect however has been implicated in the occurrence of ovarian hyperstimulation syndrome (OHSS) after hCG triggering (Haning et al., 1985) . OHSS is a serious complication of ART treatment. It may occur in donor and non-donor cycles. It affects 1-14% of all IVF or ICSI cycles (Garcia-Velasco and Pellicer, 2003) . Early severe OHSS was reported in 11.3% of 353 high responder women (Lainas et al., 2012) and in 1.3% of oocyte donors (Bodri et al., 2009) . There is worldwide emphasis on the need to eliminate the occurrence of OHSS. The last report from HEFA has shown a decline in the total number of reported cases of severe OHSS in UK (HEFA, 2017) For this reason, other alternatives were studied to substitute hCG, specially in women at high risk for OHSS. GnRHa was revived as a triggering agent after the introduction of antagonist protocols 1990s (Itskovitz-Eldor et al., 2000) . It provided a good and safe alternative in oocyte donors (Hernandez et al., 2009) . However, owing to the difference in the hormonal milieu of the luteal phase in the GnRHa and hCG triggered cycles, the pregnancy rate was disappointing in autologous cycles triggered by GnRHa (Kolibianakis et al., 2005) . The agonist binds to the pituitary GnRH receptors and replaces the antagonist, flaring up both LH and FSH, leading to oocyte maturation in a manner similar to that of natural cycles. Variations, however, exist between the natural surge and the agonist induced surge of gonadotrophins. The natural LH surge consists of three phases and lasts 48 h (Hoff et al., 1983) , while the surge produced after agonist triggering has two phases lasting 24-36 h (Itskovitz et al., 1991) . Therefore, there is a lower amount of gonadotrophins in the luteal phase of agonist triggered cycles, thus a subsequent rapid luteolysis and deficient luteal phase occur (Itskovitz et al., 1991) .
Several regimens were suggested to overcome this problem (Engmann et al., 2006 (Engmann et al., , 2008 Humaidan et al., 2010; Griffin et al., 2012; Papanikolaou et al., 2011) .
The addition of a bolus of 1500 IU hCG on the day of retrieval was suggested to rescue the luteal phase, increase the ongoing pregnancy rate (OPR) as well as eliminating the occurrence of OHSS in agonist triggered cycles. Humaidan and colleagues in a randomized controlled trial, upon 302 antagonist cycles, compared the use of 10 000 IU hCG for triggering ovulation versus using 0.5 mg GnRHa (buserelin) supplemented with 1500 IU hCG on retrieval day. Vaginal progesterone and oral estradiol were used for luteal support in both groups. None of the agonist triggered cycles developed OHSS, whereas three cases developed in the hCG group (one severe and two moderate). However, high risk patients were not included and a difference of 7% in OPR in favor of the HCG trigger group was reported (Humaidan et al., 2010) .
Another modality of rescuing luteal phase was giving intense luteal support and hormone replacement regimens, similar to the ones used for a gonadal oocyte donor recipient. The investigators recommended the use of intramuscular progesterone and high dose of estradiol during the luteal phase and early pregnancy and reported favorable outcome (Engmann et al., 2006 (Engmann et al., , 2008 . Others did not find evidence to support this modality and reported lower pregnancy and implantation rate upon using the aforementioned intense support approach (Orvieto, 2012) .
There is a need to explore for a more optimal luteal support mode in these cases. It might worth trying to combine the two aforementioned modalities and give a specialized luteal support mode in form of a bolus of 1500 IU hCG on the day of oocyte retrieval as well as giving intense hormonal support. The number of follicles, measuring ≥11 mm and/or estradiol level on the day of final oocyte maturation are among the most effective predictors for high response. In a study upon 2524 antagonist cycles, the presence ≥18 follicles, measuring ≥11 mm on trigger day was reported to have high prediction for OHSS (Papanikolaou et al., 2006) . Additionally, estradiol level ≥4000 pg/ml (14684 pmol/l) was elicited as the cutoff for high responders (percentile > 90%) among 1196 cycles (Chen et al., 2007) .
The aim of the present RCT is to compare the outcomes of antagonist cycles triggered by agonist with a specialized luteal support regimen to that triggered by hCG in ICSI patients with a high risk of OHSS. Further, to study whether the former regimen can decrease the occurrence of moderate/severe OHSS.
Patients and Methods

Study design
This randomized controlled trial was conducted during the period from June 2015 to March 2016 in a private fertility center. Women undergoing ICSI, who fulfilled the following inclusion criteria, were considered eligible for enrollment: (i) female age 18-35 years; (ii) women at high risk for OHSS, defined as having ≥18 follicles, measuring ≥11 mm and/or estradiol level ≥14684 pmol/l on the day of final oocyte maturation; and (iii) either regular cycles or oligomenorrhea/amenorrhea.
The study was approved by the institutional review board of the center and its PACTR trial registration number is PACTR 201506001132105.
Written informed consent was obtained form all participants.
Stimulation regimen
A dose between (150-225 IU) of recombinant FSH (Gonal F, Merck Serono) was commenced on the second or third day of the cycle and continued for the first 5 days. Then the dose was adjusted according to the response (monitored by ultrasound assessment and estradiol level). The
GnRH antagonist was started on Day 6 of stimulation (Cetrotide, 0.25 mg, Merck Serono). When three or more follicles reached ≥17 mm, our study participants were randomized into two groups. In group A, triggering was achieved by a subcutaneous administration of 0.3 mg of triptorelin (Decapeptyl, Ferring) followed by a dose of 1500 IU of hCG (pregnyl, Organon), 35 h after triggering. In group B, triggering was achieved by an intramuscular injection of 5000 IU of hCG (pregnyl, Organon).
Randomization
The recruited women were randomly assigned to either group in a ratio of 1:1. Overall, 190 identical sealed envelops were prepared; 95 contain 'HCG group' with all instruction details and the other 95 envelops contain 'GnRH agonist group' with all instruction details. Every recruited woman was allowed to choose one envelop once to determine to which group she was assigned.
Luteal phase support
Participants in group A received daily IM injections of progesterone, 100 mg (prontogest, Ibsa) starting from the day of retrieval and lasting for the entire luteal phase. Along with P supplementation, 2 mg E 2 valerate (cycloprogenova, Schering) was given three times daily starting from the day of retrieval and lasting for the entire luteal phase. Participants in group B received daily vaginal progesterone, 100 mg (endometrin, Ferring), three times daily starting from the day of retrieval and lasting for the entire luteal phase. E 2 valerate, 6 mg daily, was started on the day of embryo transfer (ET) and lasting for the entire luteal phase (our routine luteal support regimen) (Elgindy et al., 2010) .
In both groups, when pregnancy test was positive, the progesterone was taken vaginally in a dose of 100 mg three times daily throughout the first 8 weeks of gestation. E 2 valerate, 6 mg daily was continued up to 8 weeks of pregnancy in group A and was stopped once pregnancy was positive in group B.
Patient evaluation for OHSS
Each woman was assessed for the risk of development of OHSS on the day of oocyte retrieval and on the day of ET (according to Navot et al., 1992) . Criteria for diagnosis of mild OHSS were abdominal distension and discomfort, nausea with or without vomiting and/or diarrhea and enlarged ovaries 5-12 cm. Moderate OHSS was diagnosed by the same criteria of mild OHSS plus ultrasound evidence of ascites. Severe OHSS was diagnosed in presence of variable sized ovaries, massive ascites with or without hydrothorax, hematocrit >45%, WBC > 15000, oliguria, creatinine clearance >50 ml/min, creatinine 1.0-1.5 mg/dl, liver dysfunction and/or anasarca. If criteria of considerable (moderate or severe) OHSS were encountered, the couples were counseled about freeze all strategy. Another evaluation for OHSS development was performed after 1 week after ET.
Outcome variables
The primary outcome was the OPR. The occurrence of OHSS, clinical pregnancy rates, number of mature oocytes were the secondary outcome measures.
Clinical pregnancy was defined as positive pregnancy test and ultrasound evidence of intrauterine gestational sac 4 weeks after ET. Ongoing pregnancy was defined as clinical pregnancy continuing beyond 20 weeks of gestation.
Statistical methods
Data were described in terms of mean ± SD, median and range, or frequencies (number of cases) and percentages as appropriate. Comparison of numerical variables between the study groups was done using Student t test for independent samples in comparing normally distributed data and/ or groups >30 records, otherwise, Mann Whitney U test for independent samples was used. For comparing categorical data, Chi-squared (χ 2 ) test was performed.
Univariate and multivariate regression analysis models were used to test effect of important variable(s) on occurrence of considerable OHSS. Accuracy was represented using terms sensitivity, and specificity. Receiver operator characteristic (ROC) analysis was used to determine the optimum cutoffs for studied markers in predicting considerable OHSS. Two sided P values <0.05 was considered significant. All calculations were done using computer program IBM SPSS (Statistical Package for the Social Science; IBM Corp, Armonk, NY, USA) release 22 for Microsoft Windows.
Sample-size calculation
Ongoing pregnancy was used as the primary outcome. Chi-squared test for independent samples was used for performing the calculation. OPR was 30 and 50% in the agonist and hCG triggered cycles, respectively, in our preliminary pilot study. For an α-error of 0.05, and a power of 80% the calculated size of each group was 93 cases, and after adding a dropout rate of 2%, the final size of each group was determined to be 95.
Results
A total of 430 patients were potentially eligible for recruitment. Thirty women refused to participate, 200 did not meet the inclusion criteria, and 10 participants were excluded for other reasons (Fig. 1) . Therefore, 190 women were randomized on the day of final oocyte maturation into group A (Agonist triggering, n = 95) and group B (HCG triggering, n = 95). The two groups were balanced in respect of the demographic, clinical and ICSI cycles characteristics (Table I ). The number of participants having PCOS, according to Rotterdam criteria, was comparable between the two groups (Table I) .
Per started cycle, clinical and OPR were comparable between the two groups. The 'freeze all' policy was adopted in five women in group A and in seven women in group B. OPR per ET were 54% (49/90) in group A and 57% (50/88) in group B (Table I) . Twin pregnancy occurred in 25% (12/49) of group A and in 28% (14/50) of group B. Moderate OHSS occurred in five women in group A and in 10 women in group B with no statistical significant difference. Severe OHSS did not occur in any of the participants in group A, however, it developed in three participants in group B. When both moderate and severe degrees of OHSS were combined (considerable OHSS), a statistically significant difference was evident between both groups (P = 0.047; uncorrected Chi-square test) ( Table I) .
Univariate analysis was performed for prediction of considerable OHSS. Basal AMH, AFC, number of mature oocytes as well as estradiol level, and number of follicles ≥11 mm on trigger day were significant predictors of considerable OHSS but protocol was not which might be explained by the relatively small number of considerable OHSS cases (Table II) . Upon performing multivariate analysis, the number of follicles ≥11 mm on the trigger day was the only independent predictor. AMH and AFC had borderline significance (Table II) .
ROC analysis was performed to determine the best cutoffs for predicting considerable OHSS. Cutoff for follicles ≥11 mm was 24 (AUC: 0.846, 95% CI: 0.72-0.967, sensitivity 89% and specificity 66%) (Fig. 2a) ; AMH had cutoff value 39.3 pmol/l (AUC: 0.62, 95%CI: 0.5-0.74, sensitivity: 55.6% and specificity: 52.3%) (Fig. 2b) . Cutoff for AFC was 20 (AUC: 0.835, 95% CI: 0.753-0.917, sensitivity 89% and specificity 67%) (Fig. 2c) . For mature oocytes, cutoff was 16 (AUC: 0.84, 95% CI: 0.76-0.91, sensitivity 94.4% and specificity 67%) (Fig. 2d) . Cutoff for estradiol was 15326.4 pmol/l (AUC: 0.783, 95% CI: 0.703-0.863, sensitivity 94% and specificity 60%) (Fig. 2e) . These results are independent of protocol.
Discussion
Our study observed no difference in OPR, in antagonist cycles triggered by agonist with a specialized luteal support regimen, to that triggered by hCG in ICSI patients with a high risk of OHSS. Nevertheless, considerable OHSS was higher in the hCG triggered group. The administration of agonist for final oocyte maturation can produce a gonadotrophin surge which is sufficient for yielding a satisfactory number of mature oocytes. In current study, the number of mature oocytes was comparable between both groups. However, after agonist triggering the luteal phase is defective due to the reduced duration and concentration of the gonadotrophin surge (Itskovitz et al., 1991) with a subsequent adverse effect on corpus luteum and the endometrial function (Rao, 2001 ). The addition of 1500 IU of hCG on retrieval day has been reported to rescue the luteal phase and to achieve satisfactory mid-luteal LH and progesterone levels (Humaidan et al., 2010) However, the CPR was lower with this protocol compared to hCG triggered cycles. To further improve the pregnancy rate, Humaidan et al. (2013) evaluated the addition of a second bolus of 1500 IU hCG, 5 days after oocyte retrieval in women with low risk of OHSS. Although this regimen provided better reproductive outcomes, a higher incidence of OHSS was observed in these low risk patients. On the other hand, the ability of intensive luteal support (Engmann et al., 2008) to rescue the luteal phase specially in women with estradiol level of <4000 pg/ml on trigger day was questioned later (Engmann et al., 2016) .
In current study, we combined the addition of a bolus of 1500 IU hCG on retrieval day with intramuscular progesterone and high dose of estradiol, to test whether this package could rescue the luteal phase and provide adequate steroid levels for the endometrium. Progesterone is rapidly absorbed in the circulation when injected intramuscularly or administrated in the vagina. However, the blood levels after intramuscular administration was found to drop more slowly than after vaginal administration. Therefore, higher and frequent doses are needed to maintain the high plasma level of progesterone needed in luteal phase when using vaginal route compared to the intramuscular one. It has been suggested that the intramuscular site of progesterone administration might lead to progesterone accumulation within fatty tissue and hence working as a reservoir with continuous release that leads to a steady and more sustained concentration of progesterone in plasma compared to the vaginal or rectal rout (Nillius and Johansson, 1971) . This is in contrast to the vaginal route of administration where vaginal mucosa might act as a rate-limiting membrane that allows only a limited amount of progesterone to be absorbed, therefore contributing to the less steady blood level of progesterone (Archer et al., 1995) . Therefore, the use of intramuscular progesterone appeared as a suitable modality to ensure an adequate steroid support for the endometrium. Additionally, the use of 6 mg of estradiol was also adopted as it was shown to maintain adequate estradiol levels during the luteal phase (Elgindy et al., 2010) .
In current study, there was continuation of steroid support during early pregnancy, as earlier reports had shown that the rising hCG during early pregnancy is not sufficient to rescue the early luteolysis occurring after agonist trigger (Nevo et al., 2003) . This specialized luteal support mode succeeded in achieving an OPR comparable to the hCG triggered cycles.
Considerable OHSS was lower in the agonist triggered protocol but it was not totally eliminated. It appears that even the addition of a low dose of hCG can trigger moderate OHSS in high responders having our inclusion criteria. Humaidan et al. (2013) reported no considerable OHSS in their patients receiving agonist and one bolus of 1500 IU hCG. Patients in their study had different inclusion criteria and should have had from 15 to 25 follicles, measuring ≥11 mm on trigger day. Admittedly, the concept of agonist triggering and freeze all is suggested for high responders. There are however limitations for routine application. An optimal cryopreservation program is not available in all ART units. Larger trials are needed to confirm this concept and its superiority. In our country, it remains more acceptable for our patients to undergo fresh transfer.
Blastocyst embryo transfer (BET) increased the pregnancy rate in women with high estradiol on the day of oocyte triggering, especially for those having E 2 > 15 420 pmol/l (4200 pg/ml) (Elgindy et al., 2011) . Delaying ET offers the endometrium time to recover from any negative effects caused by the exposure to peak super-physiological levels of E2. In current study, most of participants in both groups had undergone extended culture.
Following patients for 5 days after retrieval enabled further evaluation and offering freeze all modality before undergoing BET if any manifestations of OHSS had appeared. Freeze all modality was offered to all the five women who showed OHSS in the agonist trigger group. Meanwhile, 7 of the 13 women who showed OHSS in the hCG trigger group underwent freeze all. Nevertheless, six participants developed considerable OHSS in the hCG trigger group with 4 of them having the late onset type. Two of these four cases of late onset OHSS had twin pregnancy.
OHSS is one of the most distressing complications in assisted reproduction. Nowadays, prevention of this problem is a major goal. In current study, our secondary objective was to find the most important predictors of considerable OHSS and to determine cutoffs if possible. Upon using multivariate analysis, the number of follicles ≥11 mm on trigger day was the only independent predictor. Both AMH and AFC had borderline significance.
Because we had only 18 cases with moderate/sever OHSS, we decided to perform ROC analysis only for markers that were significant in univariate analysis. Using ROC analysis, the cut off for follicles ≥11 mm was 24. Previously, a cutoff level of >25 follicles were empirically set and there has been some emphasis on the need to validate this value (Humaidan et al., 2015) . AFC cutoff was 20 with fair AUC and accuracy. The OPTIMST trial used AFC cutoff value 15 for predicting hyper response (van Tilborg et al., 2012) . Here, we report the value of 20 for predicting considerable OHSS. Basal AMH hardly touched significant level and its cutoff was 39.3 pmol/l with lower accuracy. Although the number of retrieved mature oocytes was not an independent predictor for developing considerable OHSS; yet, getting 16 mature oocytes or more had reasonable accuracy for predicting OHSS. Ji et al. (2013) in an analysis of 2455 cycles, suggested that having more than 15 oocytes increased the incidence of moderatesevere OHSS. Cutoff for E 2 was 15326.4 pmol/l on trigger day, with lower accuracy than that for follicles ≥11 mm. In a study upon 2524 antagonist cycles, E 2 levels were less reliable than the number of follicles in predicting OHSS (Papanikolaou et al., 2006) . Larger number of patients however are needed to verify current study cutoffs.
The concept of 'individualized luteal support' is emerging (Humaidan et al., 2015) . In high responders, it appears preferable to give the agonist for triggering and target either fresh transfer after giving a specialized luteal support mode or freeze all embryos if there is an estimated high OHSS risk. Based on current study findings, 24 follicles ≥11 mm on the trigger day could be an indication for opting to freeze all the embryos. larger trials are needed to confirm current study cutoffs and whether there are any additional high risk factors for predicting considerable OHSS which justify freeze all modality. Admittedly, the strategy of freezing all embryos should be applied in patients who are at high risk for OHSS.
The strength of our study is that it was adequately powered randomized study for the primary objective. Limitations are that conclusions can only apply to women meeting our selection criteria and that whereas the trial was powered adequately to detect a difference in OPR it was underpowered for OHSS. Hence larger trial using considerable OHSS as an endpoint are needed to strengthen the findings obtained from our trial. Further, we do not have access to the live birth outcome, which is important specially in OHSS cases that could have adverse perinatal outcome.
In conclusion, antagonist cycles triggered by agonist with a specialized luteal support regimen have comparable OPR to that triggered by hCG and considerable OHSS may be lower.
